Membership is surging, but Stars matter more
- Clover had 155,773 Medicare Advantage members at March 31, 2026.
- The near-term boost is real because its main PPO plans are being paid on 4.0 Stars in 2026.
- The future problem is that CMS cut the PPO plan rating to 3.5 Stars for 2026, which affects payment year 2027.
- Counterpart Health could turn Clover Assistant into a higher-margin software business, but outside adoption is still unproven.
- Management stopped reporting Normalized BER in Q1 2026, so medical cost trends are harder to read.
Fast growth meets a Star cut
The bull case is simple: Clover is adding members fast. It ended Q1 2026 with 155,773 Medicare Advantage members across five states and 203 counties. That is a big step up from 113,803 members at the end of 2025.
Clover is also getting a near-term revenue lift. In 2026, its main PPO plans are being paid on 4.0 Stars, compared with 3.5 Stars in the prior period. In Medicare Advantage, higher Star ratings can mean bonus payments from CMS, the federal agency that runs Medicare.
The bear case starts with the next payment cycle. CMS lowered Clover's flagship PPO plan rating to 3.5 Stars for 2026, which affects payment year 2027. Since the PPO plan holds almost all members, losing the current quality bonus could pressure future margins.
The software story is the swing factor. Counterpart Health lets Clover sell its Clover Assistant technology to outside Medicare Advantage payors and providers. If that works, Clover could add a higher-margin business. If it does not, the company remains mostly tied to a tough, regulated insurance market.
Premiums first, software second
Clover makes most of its money by running Medicare Advantage plans. Members enroll in PPO or HMO plans, and Clover earns premium revenue while paying for member care. The key spread is simple: collect enough premium to cover medical claims, plan costs, and overhead.
The company says Clover Assistant helps doctors find and manage chronic disease earlier. The promise is better care and lower avoidable costs. That promise matters because medical claims can move quickly when a plan adds many new members.
Clover fully exited ACO REACH starting with the 2024 performance year. That made the company simpler, with one reportable segment: Insurance. It also removed a business that had been a drag on earnings.
Counterpart Health is Clover's newer bet. It packages Clover Assistant as software and tech-enabled services for external clinicians, payors, and providers. The model could carry better margins than insurance, but Clover must prove that rivals will buy technology from a company that also runs health plans.
What Clover sells
PPO Medicare Advantage plans
This is Clover's flagship insurance product and covers the large majority of members. It is also the center of the Star rating risk because CMS cut the PPO rating to 3.5 Stars for 2026.
HMO Medicare Advantage plans
The HMO plans are smaller than the PPO plans. CMS raised the HMO plan rating to 4.0 Stars for 2026, but this helps less because most members are in PPO plans.
Clover Assistant
Clover Assistant is the company's cloud-based software for doctors. It gives data-driven prompts meant to help detect and manage chronic diseases earlier.
Counterpart Health
Counterpart Health is the outside-facing software and services business built around Clover Assistant. It could become a higher-margin growth path if external Medicare Advantage payors and providers adopt it.
One segment, PPO-heavy mix
As of March 31, 2026, Clover reported one operating segment: Insurance. The product mix is highly concentrated, with the company saying it entered 2026 with over 153,000 members and over 97% in flagship PPO plans.
What could break the thesis
PPO Star rating reset
High impact · High oddsClover's PPO plans are being paid on 4.0 Stars in 2026, which helps current revenue. CMS lowered the PPO plan rating to 3.5 Stars for 2026, affecting payment year 2027. Because the PPO plan holds almost all members, the quality bonus loss could hit the core business.
Medical costs after rapid growth
High impact · Medium oddsClover added many members quickly. New members can bring care needs that are hard to price at first. Management also stopped reporting Normalized BER in Q1 2026, which lowers visibility into underlying medical cost trends.
Counterpart Health adoption risk
Medium impact · Medium oddsThe software idea is attractive because it could carry better margins than insurance. But Clover must sell Counterpart Health to outside payors and providers, including groups that may see Clover as a competitor. Slow adoption would leave less offset against future Medicare Advantage margin pressure.
Medicare Advantage rule changes
High impact · Medium oddsClover depends on Medicare Advantage rules, CMS payments, risk adjustment, quality ratings, and drug benefit rules. In Q3 2025, the company said higher Part D cost sharing from Inflation Reduction Act changes helped drive medical claim expense growth. Future rule shifts can change revenue or costs faster than Clover can adjust pricing.
Valuation asks for proof
Medium impact · Medium oddsThe stock story already gives Clover credit for growth and a possible software upside. Finn's valuation score is weak, so the market price may leave little room for execution slips. The company needs to show that growth can turn into durable profit.
In one breath
What does Clover Health do?
Clover Health runs Medicare Advantage health plans, mainly PPO plans. It also sells technology through Counterpart Health, which is built around its Clover Assistant software.
Why do Star ratings matter for Clover Health?
Star ratings are CMS quality scores for Medicare plans. Higher ratings can bring bonus payments, so the move from 4.0 Stars in the current payment year to 3.5 Stars for the main PPO plan in payment year 2027 is a major risk.
Is Counterpart Health already proven?
Not yet. It is a promising software path, but Clover still has to prove that outside Medicare Advantage payors and providers will buy and keep using it.